Matrix Capital Management Company, LP
CIK: 0001410830
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)2 (100.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Matrix Capital Management Company, LP
Matrix Capital Management Company, LP (SEC CIK 0001410830) files insider reports with the SEC as 10% Owner of Aura Biosciences, Inc. (AURA) and 10% Owner of Zentalis Pharmaceuticals, Inc. (ZNTL).
Signal8 holds 2 ownership filings by Matrix Capital Management Company, LP, all Form 4s, filed between Dec 15, 2025 and May 11, 2026. Those filings report 2 transactions, from Dec 15, 2025 to May 7, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Matrix Capital Management Company, LP's filings is in PORTSMOUTH, NH.
Recent filings by Matrix Capital Management Company, LP
Other insiders filing for Aura Biosciences, Inc. (AURA)
- Person Julie, Chief People Officer
- Kratz Erica, Chief Reg. & Quality Officer
- Hopkins Janet Jill, Chief Medical Officer
- Elazzouzi Amy, SVP, Finance & PAO
- Abu-Absi Susan, Chief Operating Officer
- Bender Jeremy, Director